In our study, we discovered a novel signature (ARRB2, GARS, ODF2, PGK1, PKM, PLOD3, PNN, TYMP, WDR5) based on moonlighting-related genes, which was significantly associated with prognostic, immune microenvironment and therapy of PRAD patients. This evidence concerns the gene PLOD3 and prostate adenocarcinoma.